Organization (Hospital)
Liaquat National Hospital & Medical College
ClinicalTrials.gov lists Liaquat National Hospital & Medical College as lead sponsor of 33 trials. It has 29 active development programs and 13 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 6 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 8 in 2026 and about 8 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (5 to 20), forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored. 1 trial is registered to start in 2027 or later.
This page covers Liaquat National Hospital & Medical College: 33 lead-sponsored trials and 0 legal-entity registrations.
Disease areas (19)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Pain | 7 |
| Postoperative Pain | 6 |
| Agnosia | 3 |
| Anxiety Disorders | 2 |
| Ankle Injuries | 1 |
Showing 5 of 19 disease areas.
Trials by start year as sponsor or collaborator (8)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 6 |
| 2025 | 8 |
| 2024 | 7 |
| 2023 | 7 |
| 2022 | 2 |
| 2020 | 2 |
| 2019 | 1 |
| 2011 | 1 |
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (29)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Lidocaine 2% without vessel constrictor | Postoperative Pain | Phase 3 | 1 |
| Lidocaine 2% without vessel constrictor | Pain | Phase 3 | 1 |
| Intranasal Ketamine | Agnosia | Phase 1/2 | 1 |
| Dexmedetomidine Group / Group D | Hypertension | Phase 1/2 | 1 |
| Intranasal Dexmedetomidine | Agnosia | Phase 1/2 | 1 |
Showing 5 of 29 active programs.
Approved assets (13)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| DEXMEDETOMIDINE | 3 |
| TRAMADOL | 2 |
| Montelukast 10 mg | 1 |
| Lactobacillus Reuteri Probiotic | 1 |
| Bupivacain | 1 |
Showing 5 of 13 approved assets.
Journals published in (34)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| The Journal of antimicrobial chemotherapy | 3 |
| American journal of infection control | 2 |
| Annals of surgical oncology | 2 |
| The Cochrane database of systematic reviews | 2 |
| World journal of surgery | 2 |
Showing 5 of 34 journals.
Organization relationships (2)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Jinnah Postgraduate Medical Centre | Co sponsors trial with | 1 |
| Aga Khan University Hospital, Pakistan | Co sponsors trial with | 1 |
Latest dated events (35)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2027-04-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-09 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-08-20 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-05-12 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-02-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 35 events.
Biomarkers this organization publishes on (126)
Shown in this order: most publications first.
Showing 5 of 126 biomarkers.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sponsor delivery record, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarker capability evidence.